¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"M phase promoting factor"¿¡ ´ëÇÑ KI ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
attenuation factor
°¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
conversion factor
º¯È¯ÀÎÀÚ
factor
ÀÎÀÚ
predisposing factor
¼ÒÀÎ, Áúº´¼ÒÁú
Q factor
Å¥ÀÎÀÚ
rheumatoid factor
·ù¸¶Æ¼½º¾çÀÎÀÚ
risk factor
À§Çè¿äÀÎ
turbo factor
Åͺ¸ÀÎÀÚ
3D phase contrast angiography
3Â÷¿øÀ§»ó´ëÁ¶ Ç÷°üÃÔ¿µ¼ú
arterial phase
µ¿¸Æ±â
bulk phase model
µ¢¾î¸®À§»ó¸ðÇü
equilibrium phase
ÆòÇü±â
gradient induced phase shift effect
°æ»çÀ¯µµ À§»óº¯À§È¿°ú
in phase
µ¿À§»ó
in-phase image
À§»ó³»¿µ»ó
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½